CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 18-938/S-017

Trade Name:    DDAVP

Generic Name:  Desmopressin Acetate

Sponsor:       Aventis Pharmaceutical Products

Approval Date: August 8, 2002
## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Category</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Final Printed Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>EA/FONSI</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/ Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative and Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
NDA 18-938/S-017

Aventis Pharmaceutical Products
Attention: Susan Witham
Director, Drug Regulatory Affairs
Route 202-206
Box 6800
Bridgewater, NJ 08807-0800

Dear Ms. Witham:

Please refer to your supplemental new drug application dated February 11, 2002, received February 12, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for DDAVP® (desmopressin acetate) Injection, 4 µg/mL.

This "Changes Being Effected" supplemental new drug application provides for the following revisions to the carton label for the 10 X one mL ampules of 4 µg/mL DDVAP Injection.

1. Instruction regarding how to use the one point cut DDAVP ampules
2. Change in the company name from Rhone-Poulenc Rohrer to Aventis Pharmaceuticals Products Inc.
3. Minor graphic changes
4. Replacement of the caution statement: "Caution: Federal (U.S.A.) law prohibits dispensing without a prescription" with "Rx only"
5. Change in the address of Ferring AB, the manufacturer of the drug product
6. Addition of the following to the carton label:
   a. Dosage and Administration: See package insert for dosage and administration.
   b. Warning: Keep out of reach of children.
   c. Store refrigerated 2 to 8°C (36 to 46°F).

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the final printed labeling submitted February 11, 2002. Accordingly, the supplemental application is approved effective on the date of this letter.
If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Steve McCort, Regulatory Project Manager, at (301) 827-6415.

Sincerely,

[See appended electronic signature page]

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Mary Parks
8/8/02 04:28:29 PM
for Dr. Orloff
APPLICATION NUMBER:

NDA 18-939/S-017

APPROVED LABELING
Rev. XXXX

**DDAVP**

**Nasal Spray**
(desmopressin acetate)

**Rx only**

**DESCRIPTION**

**DDAVP® Nasal Spray** (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:

Mol. wt. 1183.34

Empirical formula: C₄₆H₆₆N₁₄O₁₂S₂•C₂H₄O₂•3H₂O

\[
\text{O} \\
\text{SCH₂CH₂C-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH₂ • CH₃COOH • 3H₂O}
\]

1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.

**DDAVP Nasal Spray** is provided as an aqueous solution for intranasal use.

Each mL contains:
- Desmopressin acetate 0.1 mg
- Sodium Chloride 7.5 mg
- Citric acid monohydrate 1.7 mg
- Disodium phosphate dihydrate 3.0 mg
- Benzalkonium chloride solution (50%) 0.2 mg

The **DDAVP Nasal Spray** compression pump delivers 0.1 mL (10 mcg) of DDAVP (desmopressin acetate) per spray.

**CLINICAL PHARMACOLOGY**

DDAVP contains as active substance desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (0.1 mg) of intranasal DDAVP has an antidiuretic activity of about 400 IU; 10 mcg of desmopressin acetate is equivalent to 40 IU.

1. The biphasic half-lives for intranasal DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone used in this condition. As a result, intranasal DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration.

2. The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.
3. DDAVP administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection. **Human Pharmacokinetics:** DDAVP is mainly excreted in the urine. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe renal impairment (n=24, 6 subjects in each group) receiving single dose desmopressin acetate (2mcg) injection demonstrated a difference in DDAVP terminal half-life. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment. (See CONTRAINDICATIONS.)

**INDICATIONS AND USAGE**

**Primary Nocturnal Enuresis:** DDAVP Nasal Spray is indicated for the management of primary nocturnal enuresis. It may be used alone or adjunctive to behavioral conditioning or other nonpharmacological intervention. It has been shown to be effective in some cases that are refractory to conventional therapies.

**Central Cranial Diabetes Insipidus:** DDAVP Nasal Spray is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus.

The use of DDAVP Nasal Spray in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. This will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia.

There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.

Patients are selected for therapy by establishing the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued response to intranasal DDAVP can be monitored by urine volume and osmolality.

DDAVP is also available as a solution for injection when the intranasal route may be compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.

**CONTRAINDICATIONS**

**DDAVP Nasal Spray** is contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of DDAVP Nasal Spray.
DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).

WARNINGS
1. For intranasal use only.
2. When DDAVP Nasal Spray is administered, in particular in pediatric and geriatric patients, fluid intake should be adjusted downward in order to decrease the potential occurrence of water intoxication and hyponatremia with accompanying signs and symptoms (headache, nausea/vomiting, decreased serum sodium and weight gain). (See PRECAUTIONS, Geriatric Use.) Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that may result in seizures which could lead to coma.

PRECAUTIONS
General: Intranasal DDAVP at high dosage has infrequently produced a slight elevation of blood pressure, which disappeared with a reduction in dosage. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease because of possible rise in blood pressure.

DDAVP should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, because these patients are prone to hyponatremia. Rare severe allergic reactions have been reported with DDAVP. Anaphylaxis has been reported rarely with intravenous and intranasal administration of DDAVP.

Central Cranial Diabetes Insipidus: Since DDAVP is used intranasally, changes in the nasal mucosa such as scarring, edema, or other disease may cause erratic, unreliable absorption in which case intranasal DDAVP should not be used. For such situations, DDAVP Injection should be considered.

Primary Nocturnal Enuresis: If changes in the nasal mucosa have occurred, unreliable absorption may result. DDAVP Nasal Spray should be discontinued until the nasal problems resolve.

Information for Patients: Patients should be informed that the DDAVP Nasal Spray bottle accurately delivers 50 doses of 10 mcg each. Any solution remaining after 50 doses should be discarded since the amount delivered thereafter may be substantially less than 10 mcg of drug. No attempt should be made to transfer remaining solution to another bottle. Patients should be instructed to read accompanying directions on use of the spray pump carefully before use.

Laboratory Tests: Laboratory tests for following the patient with central cranial diabetes insipidus or post-surgical or head trauma-related polyuria and polydipsia include urine volume and osmolality. In some cases plasma osmolality measurements may be required. For the healthy patient with primary nocturnal enuresis, serum electrolytes should be checked at least once if therapy is continued beyond 7 days.
Drug Interactions: Although the pressor activity of DDAVP is very low compared to the antidiuretic activity, use of large doses of intranasal DDAVP with other pressor agents should only be done with careful patient monitoring.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

Pregnancy: Category B: Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 mcg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m²) revealed no harm to the fetus due to DDAVP (desmopressin acetate). There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Several publications of desmopressin acetate’s use in the management of diabetes insipidus during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. However, no causal connection between these events and desmopressin acetate has been established. A fifteen year Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in antidiuretic doses has no uterotonic action and the physician will have to weigh the therapeutic advantages against the possible risks in each case.

Nursing Mothers: There have been no controlled studies in nursing mothers. A single study in a post-partum woman demonstrated a marked change in plasma, but little if any change in assayable DDAVP in breast milk following an intranasal dose of 10 mcg. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to a nursing woman.

Pediatric Use: Primary Nocturnal Enuresis: DDAVP Nasal Spray (desmopressin acetate) has been used in childhood nocturnal enuresis. Short-term (4-8 weeks) DDAVP Nasal Spray administration has been shown to be safe and modestly effective in pediatric patients aged 6 years or older with severe childhood nocturnal enuresis. Adequately controlled studies with intranasal DDAVP in primary nocturnal enuresis have not been conducted beyond 4-8 weeks. The dose should be individually adjusted to achieve the best results.

Central Cranial Diabetes Insipidus: DDAVP Nasal Spray has been used in children with diabetes insipidus. Use in infants and children will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. The dose must be individually adjusted to the patient with attention in the very young to the danger of an extreme decrease in plasma osmolality with resulting convulsions. Dose should start at 0.05 mL or less.
Since the spray cannot deliver less than 0.1 mL (10 mcg), smaller doses should be administered using the rhinal tube delivery system. Do not use the nasal spray in pediatric patients requiring less than 0.1 mL (10 mcg) per dose.

Geriatric Use: Clinical studies of DDAVP Nasal Spray did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 ml/min). (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics and CONTRAINDICATIONS.)

Use of DDAVP Nasal Spray in geriatric patients will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. (See WARNINGS).

There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.

ADVERSE REACTIONS

Infrequently, high dosages of intranasal DDAVP have produced transient headache and nausea. Nasal congestion, rhinitis and flushing have also been reported occasionally along with mild abdominal cramps. These symptoms disappeared with reduction in dosage. Nosebleed, sore throat, cough and upper respiratory infections have also been reported.

The following table lists the percentage of patients having adverse experiences without regard to relationship to study drug from the pooled pivotal study data for nocturnal enuresis.

<table>
<thead>
<tr>
<th>ADVERSE REACTION</th>
<th>PLACEBO (N=59)</th>
<th>DDAVP 20 mcg (N=60)</th>
<th>DDAVP 40 mcg (N=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>BODY AS A WHOLE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Asthenia</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Chills</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Headache</td>
<td>0</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Throat Pain</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Count 1</td>
<td>Count 2</td>
<td>Count 3</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Dizziness</strong></td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td><strong>RESPIRATORY SYSTEM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Nostril Pain</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory Infection</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>2</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td><strong>CARDIOVASCULAR SYSTEM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasodilation</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>DIGESTIVE SYSTEM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Disorder</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td><strong>SKIN &amp; APPENDAGES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leg Rash</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>SPECIAL SENSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Edema Eyes</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Lachrymation Disorder</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

See **WARNINGS** for the possibility of water intoxication and hyponatremia.

**OVERDOSAGE**
(See **ADVERSE REACTIONS**.) In case of overdosage, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. There is no known specific antidote for desmopressin acetate or **DDAVP Nasal Spray**.

An oral LD₃₀ has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.

**DOSAGE AND ADMINISTRATION**

**Primary Nocturnal Enuresis:** Dosage should be adjusted according to the individual. The recommended initial dose for those 6 years of age and older is 20 mcg or 0.2 mL solution intranasally at bedtime. It is recommended that one-half of the dose be administered per nostril. Adjustment up to 40 mcg is suggested if the patient does not respond.

Some patients may respond to 10 mcg and adjustment to that lower dose may be done if the patient has shown a response to 20 mcg. For patients receiving 10 mcg the dose should be administered in one nostril. Adequately controlled studies with intranasal DDAVP in primary nocturnal enuresis have not been conducted beyond 4-8 weeks.

**Central Cranial Diabetes Insipidus:** **DDAVP Nasal Spray** dosage must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients with nasal congestion and blockage have often responded well to intranasal DDAVP. The usual dosage range in adults is 0.1 to 0.4 mL daily, either as a single dose or divided into two or three doses. Most adults require 0.2 mL daily in two divided doses.
The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For children aged 3 months to 12 years, the usual dosage range is 0.05 to 0.3 mL daily, either as a single dose or divided into two doses. About 1/4 to 1/3 of patients can be controlled by a single daily dose of DDAVP administered intranasally.

The nasal spray pump can only deliver doses of 0.1 mL (10 mcg) or multiples of 0.1 mL. If doses other than those are required, the rhinal tube delivery system may be used.

The spray pump must be primed prior to the first use. To prime pump, press down four times. The bottle will now deliver 10 mcg of drug per spray. Discard DDAVP Nasal Spray after 50 sprays since the amount delivered thereafter per spray may be substantially less than 10 μg of drug.

Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics, CONTRAINDICATIONS, and PRECAUTIONS, Geriatric Use.)

HOW SUPPLIED
DDAVP Nasal Spray is available in a 5-mL bottle with spray pump delivering 50 sprays of 10 mcg (NDC 0075-2452-01). Desmopressin acetate is also available as DDAVP Rhinal Tube, a refrigerated product with 2.5 mL per vial, packaged with two rhinal tube applicators per carton (NDC 0075-2450-01).

Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP]. STORE BOTTLE IN UPRIGHT POSITION.

Keep out of the reach of children.

U.S. Patent Nos. 5,498,598; 5,500,413; 5,596,078; 5,674,850; 5,763,407

Manufactured for
Aventis Pharmaceuticals Inc.
Bridgewater, NJ 08807
By Ferring AB, Soldattorpsvägen 5,
SE-200 61 Limhamn, Sweden

Rev. XXXX 2004
©XXXX Aventis Pharmaceuticals Inc.
PATIENT INSTRUCTION GUIDE

DDAVP® Nasal Spray
(desmopressin acetate)

A better way to deliver DDAVP®

Delivering DDAVP® more efficiently
Your doctor has prescribed DDAVP as antidiuretic hormone replacement therapy. Follow the dosage schedule that is specified. The convenient nasal spray pump provides an efficient, reliable way to administer your medication. It is important, however, to adhere completely to the following instructions so that you will always receive a consistent dose of your medication.

CAUTION: The nasal spray pump accurately delivers 50 doses of 10 micrograms each. Any solution remaining after 50 doses should be discarded since the amount delivered thereafter per actuation may be substantially less than 10 micrograms of drug. Do not transfer any remaining solution to another bottle. Please read the following instructions carefully before using the spray pump.

Using your DDAVP® Nasal Spray Pump
1. Remove protective cap.

2. The spray pump must be primed prior to the first use. To prime pump, press down 4 times.

3. Once primed, the spray pump delivers 10 micrograms of medication each time it is pressed. To ensure dosing accuracy, tilt bottle so that dip tube inside the bottle draws from the deepest portion of the medication.

![Correct](correct.png)

![Incorrect](incorrect.png)

To administer a 10-microgram dose, place the spray nozzle in nostril and press the spray pump once. If a higher dose has been prescribed, spray half the dose in each nostril. The spray pump cannot be used for doses less than 10 micrograms or doses other than multiples of 10 micrograms.
4. Replace the protective cap on bottle after use. The pump will stay primed for up to one week. If the product has not been used for a period of one week, re-prime the pump by pressing once.

5. We have included a convenient check-off chart to assist you in keeping track of medication doses used. This will help assure that you receive 50 “full doses” of medication. Please note that the bottle has been filled with extra solution to accommodate the initial priming activity.

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>22</td>
<td>23</td>
<td>24</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>27</td>
<td>28</td>
<td>29</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>32</td>
<td>33</td>
<td>34</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>37</td>
<td>38</td>
<td>39</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>42</td>
<td>43</td>
<td>44</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>47</td>
<td>48</td>
<td>49</td>
<td>50</td>
<td></td>
</tr>
</tbody>
</table>

1. Retain with medication or affix in convenient location.

2. Starting with dose #1, check off after each administration.

3. **Discard medication after 50 doses.**

Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP].

**STORE BOTTLE IN UPRIGHT POSITION.**

Manufactured for
Aventis Pharmaceuticals Inc.
Bridgewater, NJ 08807
By Ferring AB, Soldattorpsvägen 5,
SE-200 61 Limhamn, Sweden

Rev. XXXX
©2004 Aventis Pharmaceuticals Inc.
Rev. XXXX

**DDAVP®**

*Rhinal Tube*

(desmopressin acetate)

**Rx only**

**DESCRIPTION**

**DDAVP® Rhinal Tube** (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:

Empirical formula: \( \text{C}_{40}\text{H}_{64}\text{N}_{14}\text{O}_{12}\text{S}_{2}\cdot\text{C}_{2}\text{H}_{4}\text{O}_{2}\cdot3\text{H}_{2}\text{O} \)

\[
\begin{array}{ccccccccccc}
\text{O} & | & \text{SCH}_2\text{CH}_2\text{C-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH}_2 & \cdot & \text{CH}_3\text{COOH} & \cdot & 3\text{H}_2\text{O} \\
1 & 2 & 3 & 4 & 5 & 6 & 7 & 8 & 9 & 10
\end{array}
\]

1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.

**DDAVP Rhinal Tube** is provided as an aqueous solution for intranasal use.

Each mL contains:

- Desmopressin acetate: 0.1 mg
- Chlorobutanol: 5.0 mg
- Sodium Chloride: 9.0 mg
- Hydrochloric acid to adjust pH to approximately 4

**CLINICAL PHARMACOLOGY**

**DDAVP Rhinal Tube** contains as active substance desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (0.1 mg) of intranasal DDAVP (desmopressin acetate) has an antidiuretic activity of about 400 IU; 10 mcg of desmopressin acetate is equivalent to 40 IU.

1. The biphasic half-lives for intranasal DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone used in this condition. As a result, intranasal DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration.

2. The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.

3. DDAVP administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection.

**Human Pharmacokinetics:** DDAVP is mainly excreted in the urine. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe renal impairment (n=24,
6 subjects in each group) receiving single dose desmopressin acetate (2mcg) injection demonstrated a
difference in DDAVP terminal half-life. Terminal half-life significantly increased from 3 hours in
normal healthy patients to 9 hours in patients with severe renal impairment.
(See CONTRAINDICATIONS.)

INDICATIONS AND USAGE

Primary Nocturnal Enuresis: DDAVP Rhinal Tube is indicated for the management of
primary nocturnal enuresis. It may be used alone or adjunctive to behavioral conditioning or
other non-pharmacological intervention. It has been shown to be effective in some cases that are
refractory to conventional therapies.

Central Cranial Diabetes Insipidus: DDAVP Rhinal Tube is indicated as antidiuretic
replacement therapy in the management of central cranial diabetes insipidus and for management
of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary
region. It is ineffective for the treatment of nephrogenic diabetes insipidus.

The use of DDAVP Rhinal Tube in patients with an established diagnosis will result in a
reduction in urinary output with increase in urine osmolality and a decrease in plasma
osmolality. This will allow the resumption of a more normal life-style with a decrease in urinary
frequency and nocturia.

There are reports of an occasional change in response with time, usually greater than 6 months.
Some patients may show a decreased responsiveness, others a shortened duration of effect. There
is no evidence this effect is due to the development of binding antibodies but may be due to a
local inactivation of the peptide.

Patients are selected for therapy by establishing the diagnosis by means of the water deprivation
test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued
response to intranasal DDAVP can be monitored by urine volume and osmolality.

DDAVP is also available as a solution for injection when the intranasal route may be
compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy
of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate
where there is an impaired level of consciousness. In addition, cranial surgical procedures, such
as transsphenoidal hypophysectomy create situations where an alternative route of administration
is needed as in cases of nasal packing or recovery from surgery.

CONTRAINDICATIONS

DDAVP Rhinal Tube is contraindicated in individuals with known hypersensitivity to
desmopressin acetate or to any of the components of DDAVP Rhinal Tube.

DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a
creatinine clearance below 50ml/min).

WARNINGS

1. For intranasal use only.

2. When DDAVP is administered, in particular, in pediatric and geriatric patients, fluid intake
should be adjusted downward in order to decrease the potential occurrence of water
intoxication and hyponatremia with accompanying signs and symptoms (headache,
nausea/vomiting, decreased serum sodium and weight gain). (See PRECAUTIONS, Geriatric Use.) Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that may result in seizures which could lead to coma.

PRECAUTIONS

General: Intranasal DDAVP at high dosage has infrequently produced a slight elevation of blood pressure, which disappeared with a reduction in dosage. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease because of possible rise in blood pressure.

DDAVP should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, because these patients are prone to hyponatremia. Rare severe allergic reactions have been reported with DDAVP. Anaphylaxis has been reported rarely with intravenous and intranasal administration of DDAVP.

Central Cranial Diabetes Insipidus: Since DDAVP Rhinal Tube is used intranasally, changes in the nasal mucosa such as scarring, edema, or other disease may cause erratic, unreliable absorption in which case intranasal DDAVP should not be used. For such situations, DDAVP Injection should be considered.

Primary Nocturnal Enuresis: If changes in the nasal mucosa have occurred, unreliable absorption may result. DDAVP Rhinal Tube should be discontinued until the nasal problems resolve.

Laboratory Tests: Laboratory tests for following the patient with central cranial diabetes insipidus or post-surgical or head trauma-related polyuria and polydipsia include urine volume and osmolality. In some cases plasma osmolality measurements may be required. For the healthy patient with primary nocturnal enuresis, serum electrolytes should be checked at least once if therapy is continued beyond 7 days.

Drug Interactions: Although the pressor activity of DDAVP is very low compared to the antidiuretic activity, use of large doses of intranasal DDAVP with other pressor agents should only be done with careful patient monitoring.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

Pregnancy Category B: Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 mcg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m²) revealed no harm to the fetus due to DDAVP. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Several publications of desmopressin acetate’s use in the management of diabetes insipidus during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. However, no causal connection between these events and desmopressin acetate has been established. A fifteen year, Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in
antidiuretic doses has no uterotonic action and the physician will have to weigh the therapeutic advantages against the possible risks in each case.

Nursing Mothers: There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP® (desmopressin acetate) in breast milk following an intranasal dose of 10 mcg. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to a nursing woman.

Pediatric Use: Primary Nocturnal Enuresis: DDAVP Rhinal Tube (desmopressin acetate) has been used in childhood nocturnal enuresis. Short-term (4-8 weeks) DDAVP Rhinal Tube administration has been shown to be safe and modestly effective in pediatric patients aged 6 years or older with severe childhood nocturnal enuresis. Adequately controlled studies with intranasal DDAVP in primary nocturnal enuresis have not been conducted beyond 4-8 weeks. The dose should be individually adjusted to achieve the best results.

Central Cranial Diabetes Insipidus: DDAVP Rhinal Tube has been used in pediatric patients with diabetes insipidus. Use in infants and pediatric patients will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. The dose must be individually adjusted to the patient with attention in the very young to the danger of an extreme decrease in plasma osmolality with resulting convulsions. Dose should start at 0.05 mL or less.

There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.

Geriatric Use: Clinical studies of DDAVP Rhinal Tube did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).

(See CLINICAL PHARMACOLOGY, Human Pharmacokinetics and CONTRAINDICATIONS.)

Use of DDAVP Rhinal Tube in geriatric patients will require careful fluid intake restrictions to prevent possible hyponatremia and water intoxication. (See WARNINGS.)

ADVERSE REACTIONS

Infrequently, high dosages of intranasal DDAVP have produced transient headache and nausea. Nasal congestion, rhinitis and flushing have also been reported occasionally along with mild abdominal cramps. These symptoms disappeared with reduction in dosage. Nosebleed, sore throat, cough and upper respiratory infections have also been reported.
The following table lists the percent of patients having adverse experiences without regard to relationship to study drug from the pooled pivotal study data for nocturnal enuresis.

<table>
<thead>
<tr>
<th>ADVERSE REACTION</th>
<th>PLACEBO (N=59) %</th>
<th>DDAVP 20 mcg (N=60) %</th>
<th>DDAVP 40 mcg (N=61) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>BODY AS A WHOLE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Asthenia</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Chills</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Headache</td>
<td>0</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Throat Pain</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>RESPIRATORY SYSTEM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Nostril Pain</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Respiratory Infection</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>2</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>CARDIOVASCULAR SYSTEM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasodilation</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DIGESTIVE SYSTEM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Disorder</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>SKIN &amp; APPENDAGES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leg Rash</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>SPECIAL SENSES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Edema Eyes</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Lachrymation Disorder</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

See **WARNINGS** for the possibility of water intoxication and hyponatremia.

**OVERDOSAGE**

(See **ADVERSE REACTIONS.**) In case of overdosage, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. There is no known specific antidote for desmopressin acetate or DDAVP Rhinal Tube.

An oral LD<sub>50</sub> has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.
DOSAGE AND ADMINISTRATION

Primary Nocturnal Enuresis: Dosage should be adjusted according to the individual. The recommended initial dose for those 6 years of age and older is 20 mcg or 0.2 mL solution intranasally at bedtime. Adjustment up to 40 mcg is suggested if the patient does not respond. Some patients may respond to 10 mcg and adjustment to that lower dose may be done if the patient has shown a response to 20 mcg. It is recommended that one-half of the dose be administered per nostril. Adequately controlled studies with intranasal DDAVP in primary nocturnal enuresis have not been conducted beyond 4-8 weeks.

Central Cranial Diabetes Insipidus: This drug is administered into the nose through a soft, flexible plastic rhinal tube which has four graduation marks on it that measure 0.2, 0.15, 0.1 and 0.05 mL. DDAVP Rhinal Tube dosage must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients with nasal congestion and blockage have often responded well to intranasal DDAVP. The usual dosage range in adults is 0.1 to 0.4 mL daily, either as a single dose or divided into two or three doses. Most adults require 0.2 mL daily in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For children aged 3 months to 12 years, the usual dosage range is 0.05 to 0.3 mL daily, either as a single dose or divided into two doses. About 1/4 to 1/3 of patients can be controlled by a single daily dose of DDAVP administered intranasally.

Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics, CONTRAINDICATIONS, and PRECAUTIONS, Geriatric Use.)

HOW SUPPLIED

DDAVP Rhinal Tube is available in a 2.5 mL bottle, packaged with two rhinal tube applicators per carton (NDC 0075-2450-01). Also available in a 5.0 mL pump bottle with spray pump delivering 50 doses of 10 mcg (NDC 0075-2452-01).

Store refrigerated 2 to 8°C (36 to 46°F). When traveling, closed bottles will maintain stability for 3 weeks when stored at controlled room temperature, 20 to 25°C (68 to 77°F).

Keep out of the reach of children.

MILITARY: DDAVP Rhinal Tube, 1 x 2.5 mL (NSN 6505-01-145-6338).

Manufactured for
Aventis Pharmaceuticals Inc.
Bridgewater, NJ 08807
By Ferring AB, Soldattorpsvägen 5,
SE-200 61 Limhamn, Sweden

US Patent Nos. 5,500,413; 5,596,078; 5,674,850; 5,763,407
PATIENT INSTRUCTION GUIDE

DDAVP®
Rhinal Tube
(desmopressin acetate)

1. Pull plastic tag on neck of bottle.

2. Break security seal and remove plastic cap.

3. Twist off the small knurled seal from the dropper. Use the same seal reversed to prevent subsequent leakage, especially if the bottle is not stored upright.
4. The drug is administered by a soft, flexible, plastic rhinal tube which has dose marks at 0.2, 0.15, 0.1 and 0.05 mL. Take the arrow-marked part of the tube in one hand and place the fingers of the other hand around the cylindrical part of the closure. Insert the top of the dropper in a downward position into the arrow-marked end of the tube and squeeze the dropper until the solution has reached the desired calibration mark. The dose is measured from the arrow-marked end of the tube to the appropriate calibration. Disconnect the tube from the bottle by withdrawing the bottle quickly downwards. In order to prevent air bubbles from forming in the tube, maintain constant pressure on the dropper. If difficulty is experienced in filling the tube, a diabetic or tuberculin syringe may be used to draw up the dose and load the tube.

5. Hold the tube with the fingers approximately ¼ inch from the end and insert into a nostril until the tips of the fingers reach the nostril.
6. Put the other end of the tube into the mouth. Hold the breath, tilt the head back and then blow with a short, strong puff through the tube so that the solution reaches the right place in the nasal cavity. Through this procedure, medication is limited to the nasal cavity and the preparation does not pass down into the throat.
In very young patients, it may be necessary for an adult to blow the solution into the child’s nose. In such cases, the tube will not need to be put into the nose as far as in the older child or adult. The tube should be placed in the nose gently just far enough so that the solution does not run out. A baby must be held firmly and securely.

7. After use, reseal dropper tip and close the bottle with the plastic cap. Wash the tube in water and shake thoroughly, until no more water is left. The tube can then be used for the next application.

IMPORTANT:
Replace Knurled Seal
Store refrigerated 2 to 8°C (36 to 46°F). When traveling, closed bottles will maintain stability for 3 weeks when stored at controlled room temperature, 20 to 25°C (68 to 77°F).

Manufactured for
Aventis Pharmaceuticals Inc.
Bridgewater, NJ 08807
By Ferring AB, Soldattorpsvägen 5,
SE-200 61 Limhamn, Sweden

Rev. XXXX
DDAVP® Injection
(desmopressin acetate)
4 mcg/mL
Rx only

Rev. XXXX 2004

DESCRIPTION

DDAVP® Injection (desmopressin acetate) 4 mcg/mL is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:

Mol. Wt. 1183.34

![Chemical Structure]

Empirical Formula: C₄₆H₆₄N₁₄O₁₂S₂•C₃H₄O₂•3H₂O

1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.

DDAVP Injection 4 mcg/mL is provided as a sterile, aqueous solution for injection.

Each mL provides:

- Desmopressin acetate 4.0 mcg
- Sodium chloride 9.0 mg
- Hydrochloric acid to adjust pH to 4

The 10 mL vial contains chlorobutanol as a preservative (5.0 mg/mL).

CLINICAL PHARMACOLOGY

DDAVP Injection 4 mcg/mL contains as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (4 mcg) of DDAVP (desmopressin acetate) solution has an antidiuretic activity of about 16 IU; 1 mcg of DDAVP is equivalent to 4 IU.

DDAVP has been shown to be more potent than arginine vasopressin in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand's disease Type I.

Dose-response studies were performed in healthy persons, using doses of 0.1 to 0.4 mcg/kg body weight, infused over a 10-minute period. Maximal dose response occurred at 0.3 to 0.4 mcg/kg. The response to DDAVP of factor VIII activity and plasminogen activator is dose-related, with maximal plasma levels of 300 to 400 percent of initial concentrations obtained after infusion of 0.4 mcg/kg body weight. The increase is rapid and evident within 30 minutes, reaching a maximum at a point ranging from 90 minutes to two hours. The factor VIII related antigen and ristocetin cofactor activity were also increased to a smaller degree, but still are dose-dependent.

1. The biphasic half-lives of DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, respectively, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone. As a result, DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration.
2. The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.

3. When administered by injection, DDAVP has an antidiuretic effect about ten times that of an equivalent dose administered intranasally.

4. The bioavailability of the subcutaneous route of administration was determined qualitatively using urine output data. The exact fraction of drug absorbed by that route of administration has not been quantitatively determined.

5. The percentage increase of factor VIII levels in patients with mild hemophilia A and von Willebrand's disease was not significantly different from that observed in normal healthy individuals when treated with 0.3 mcg/kg of DDAVP infused over 10 minutes.

6. Plasminogen activator activity increases rapidly after DDAVP infusion, but there has been no clinically significant fibrinolysis in patients treated with DDAVP.

7. The effect of repeated DDAVP administration when doses were given every 12 to 24 hours has generally shown a gradual diminution of the factor VIII activity increase noted with a single dose. The initial response is reproducible in any particular patient if there are 2 or 3 days between administrations.

**Human Pharmacokinetics:** DDAVP is mainly excreted in the urine. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe renal impairment (n=24, 6 subjects in each group) receiving single dose desmopressin acetate (2mcg) injection demonstrated a difference in DDAVP terminal half-life. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.

(See **CONTRAINDICATIONS**.)

**INDICATIONS AND USAGE**

**Hemophilia A:** DDAVP Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%.

DDAVP will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure.

DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.

**DDAVP is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies.**

In certain clinical situations, it may be justified to try DDAVP in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored.

**von Willebrand's Disease (Type I):** DDAVP Injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand's disease (Type I) with factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in patients with mild to moderate von Willebrand's disease.
during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure.

DDAVP will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.

Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of DDAVP to ensure that adequate levels are being achieved.

DDAVP is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. (See WARNINGS.)

**Diabetes Insipidus: DDAVP Injection 4 mcg/mL** is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus.

DDAVP is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.

**CONTRAINDICATIONS**

**DDAVP Injection 4 mcg/mL** is contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of **DDAVP Injection 4 mcg/mL**.

DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).

**WARNINGS**

When DDAVP Injection is administered to patients who do not have need of antidiuretic hormone for its antidiuretic effect, in particular in pediatric and geriatric patients, fluid intake should be adjusted downward to decrease the potential occurrence of water intoxication and hyponatremia with accompanying signs and symptoms (headache, nausea/vomiting, decreased serum sodium and weight gain). (See PRECAUTIONS, Geriatric Use.)

Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that may result in seizures which could lead to coma.

DDAVP should not be used to treat patients with Type IIB von Willebrand’s disease since platelet von Willebrand factor aggregation may be induced.

**PRECAUTIONS**

**General:** For injection use only.
**DDAVP® Injection** (desmopressin acetate) 4 mcg/mL has infrequently produced changes in blood pressure causing either a slight elevation in blood pressure or a transient fall in blood pressure and a compensatory increase in heart rate. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

DDAVP (desmopressin acetate) should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, because these patients are prone to hyponatremia.

There have been rare reports of thrombotic events following DDAVP Injection 4 mcg/mL in patients predisposed to thrombus formation. No causality has been determined, however, the drug should be used with caution in these patients.

Severe allergic reactions have been reported rarely. Anaphylaxis has been reported rarely with intravenous and intranasal DDAVP, including isolated cases of fatal anaphylaxis with intravenous DDAVP. It is not known whether antibodies to DDAVP Injection 4 mcg/mL are produced after repeated injections.

**Hemophilia A:** Laboratory tests for assessing patient status include levels of factor VIII coagulant, factor VIII antigen and factor VIII ristocetin cofactor (von Willebrand factor) as well as activated partial thromboplastin time. Factor VIII coagulant activity should be determined before giving DDAVP for hemostasis. If factor VIII coagulant activity is present at less than 5% of normal, DDAVP should not be relied on.

**von Willebrand’s Disease:** Laboratory tests for assessing patient status include levels of factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand factor antigen. The skin bleeding time may be helpful in following these patients.

**Diabetes Insipidus:** Laboratory tests for monitoring the patient include urine volume and osmolality. In some cases, plasma osmolality may be required.

**Drug Interactions:** Although the pressor activity of DDAVP is very low compared with the antidiuretic activity, use of doses as large as 0.3 mcg/kg of DDAVP with other pressor agents should be done only with careful patient monitoring.

DDAVP has been used with epsilon aminocaproic acid without adverse effects.

**Carcinogenicity, Mutagenicity, Impairment of Fertility:** Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

**Pregnancy Category B:** Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 mcg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m²) revealed no harm to the fetus due to DDAVP. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Several publications of desmopressin acetate’s use in the management of diabetes insipidus during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. However, no causal connection between these events and desmopressin acetate has been established. A fifteen year, Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low. As opposed to preparations
containing natural hormones, desmopressin acetate in antidiuretic doses has no uterotonic action and the physician will have to weigh the therapeutic advantages against the possible risks in each case.

**Nursing Mothers:** There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP in breast milk following an intranasal dose of 10 mcg. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to a nursing woman.

**Pediatric Use:** Use in infants and pediatric patients will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. **DDAVP Injection** 4 mcg/mL should not be used in infants less than three months of age in the treatment of hemophilia A or von Willebrand’s disease; safety and effectiveness in pediatric patients under 12 years of age with diabetes insipidus have not been established.

**Geriatric Use:** Clinical studies of DDAVP Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min). (See **CLINICAL PHARMACOLOGY**, Human Pharmacokinetics and CONTRAINDICATIONS.)

Use of DDAVP injection in geriatric patients will require careful fluid intake restrictions to prevent possible hyponatremia and water intoxication. (See **WARNINGS**.)

**ADVERSE REACTIONS**

Infrequently, DDAVP has produced transient headache, nausea, mild abdominal cramps and vulval pain. These symptoms disappeared with reduction in dosage. Occasionally, injection of DDAVP has produced local erythema, swelling or burning pain. Occasional facial flushing has been reported with the administration of DDAVP. **DDAVP Injection** has infrequently produced changes in blood pressure causing either a slight elevation or a transient fall and a compensatory increase in heart rate. Severe allergic reactions including anaphylaxis have been reported rarely with **DDAVP Injection**.

See **WARNINGS** for the possibility of water intoxication and hyponatremia.

There have been rare reports of thrombotic events (acute cerebrovascular thrombosis, acute myocardial infarction) following **DDAVP Injection** in patients predisposed to thrombus formation.

**OVERDOSAGE**

(See **ADVERSE REACTIONS**.) In case of overdose, the dosage should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition.

There is no known specific antidote for desmopressin acetate or **DDAVP Injection** 4 mcg/mL.

An oral LD₅₀ has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.
DOSAGE AND ADMINISTRATION

Hemophilia A and von Willebrand's Disease (Type I): DDAVP Injection 4 mcg/mL is administered as an intravenous infusion at a dose of 0.3 mcg DDAVP/kg body weight diluted in sterile physiological saline and infused slowly over 15 to 30 minutes. In adults and children weighing more than 10 kg, 50 mL of diluent is recommended; in children weighing 10 kg or less, 10 mL of diluent is recommended. Blood pressure and pulse should be monitored during infusion. If DDAVP Injection 4 mcg/mL is used preoperatively, it should be administered 30 minutes prior to the scheduled procedure.

The necessity for repeat administration of DDAVP or use of any blood products for hemostasis should be determined by laboratory response as well as the clinical condition of the patient. The tendency toward tachyphylaxis (lessening of response) with repeated administration given more frequently than every 48 hours should be considered in treating each patient.

Diabetes Insipidus: This formulation is administered subcutaneously or by direct intravenous injection. DDAVP Injection 4 mcg/mL dosage must be determined for each patient and adjusted according to the pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover.

The usual dosage range in adults is 0.5 mL (2.0 mcg) to 1 mL (4.0 mcg) daily, administered intravenously or subcutaneously, usually in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For patients who have been controlled on intranasal DDAVP and who must be switched to the injection form, either because of poor intranasal absorption or because of the need for surgery, the comparable antidiuretic dose of the injection is about one-tenth the intranasal dose.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics, CONTRAINDICATIONS, and PRECAUTIONS, Geriatric Use.)

Directions for use of One Point Cut (OPC) Ampules for DDAVP Injection:

1. Use aseptic technique to clean ampule. Gently tap the top of the ampule to assist the flow of the solution from the upper portion of the ampule to the lower portion.
2. Locate the blue dot on the upper portion of the ampule. Below this dot is a small score on the neck of the ampule. Hold the ampule with the blue dot facing away from you.
3. Cover the vial with an appropriate wipe. Apply pressure to the top and bottom portions of the ampule to snap the ampule open away from you.

HOW SUPPLIED

DDAVP Injection 4 mcg/mL is available as a sterile solution in cartons of ten 1 mL single-dose ampules (NDC 0075-2451-01) and in 10 mL multiple-dose vials (NDC 0075-2451-53), each containing 4.0 mcg DDAVP per mL.
Store refrigerated 2 to 8°C (36 to 46°F).

Keep out of the reach of children.

Manufactured for
Aventis Pharmaceuticals Inc.
Bridgewater, NJ 08807
By Ferring AB, Soldattorpsvägen 5
SE-200 61 Limhamn, Sweden

1.1 US Patents 5,500,413; 5,596,078; 5,763,407

Rev. XXXX 2004
©XXXX Aventis Pharmaceuticals Inc.
Rev. XXXX 2004

**DDAVP® Tablets**
(desmopressin acetate)
Rx only

**DESCRIPTION**

**DDAVP® Tablets** (desmopressin acetate) are a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:

Mol. Wt. 1183.34  
Empirical Formula: C₄₆H₆₄N₁₄O₁₂S₂ • C₂H₄O₂ • 3H₂O

\[
\text{SCH}_2\text{CH}₂\text{-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH}_2\text{-CH}_3\text{COOH•3H}_2\text{O}
\]

1-(3-mercapto propionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.

**DDAVP Tablets** contain either 0.1 or 0.2 mg desmopressin acetate. Inactive ingredients include: lactose, potato starch, magnesium stearate and povidone.

**CLINICAL PHARMACOLOGY**

**DDAVP Tablets** contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin.

**Central Diabetes Insipidus:** Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg to 0.4 mg produced clinically significant antidiuretic effects. In most patients, doses of 0.1 mg to 0.2 mg produced optimal antidiuretic effects lasting up to eight hours. With doses of 0.4 mg, antidiuretic effects were observed for up to 12 hours; measurements beyond 12 hours were not recorded. Increasing oral doses produced dose dependent increases in the plasma levels of DDAVP (desmopressin acetate).

The plasma half-life of DDAVP followed a monoexponential time course with \( t_{1/2} \) values of 1.5 to 2.5 hours which was independent of dose.

The bioavailability of DDAVP oral tablets is about 5% compared to intranasal DDAVP, and about 0.16% compared to intravenous DDAVP. The time to reach maximum plasma DDAVP levels ranged from 0.9 to 1.5 hours following oral or intranasal administration, respectively.

Following administration of **DDAVP Tablets**, the onset of antidiuretic effect occurs at around 1 hour, and it reaches a maximum at about 4 to 7 hours based on the measurement of increased urine osmolality.

The use of **DDAVP Tablets** in patients with an established diagnosis will result in a reduction in urinary output with an accompanying increase in urine osmolality. These effects usually will allow resumption of a more normal life style, with a decrease in urinary frequency and nocturia.

There are reports of an occasional change in response to the intranasal formulations of DDAVP (DDAVP Nasal Spray and DDAVP Rhinal Tube). Usually, the change occurred over a period of time greater than six months. This change may be due to decreased responsiveness, or to shortened duration of effect. There is no evidence that this effect is due to the development of binding antibodies, but may be due to a local inactivation of the peptide. No lessening of effect was observed in the 46 patients who were treated with **DDAVP Tablets** for 12 to 44 months and no serum antibodies to desmopressin were detected.

The change in structure of arginine vasopressin to desmopressin acetate resulted in less vasopressor activity and decreased action on visceral smooth muscle relative to enhanced antidiuretic activity. Consequently, clinically effective antidiuretic doses are usually below the threshold for effects on vascular or visceral smooth muscle. In the four long-term studies of **DDAVP Tablets**, no increases in blood pressure in 46 patients receiving **DDAVP Tablets** for periods of 12 to 44 months were reported.

In one study, the pharmacodynamic characteristics of **DDAVP Tablets** and intranasal formulation were compared during an 8-hour dosing interval at steady state. The doses administered to 36 hydrated (water loaded) healthy male adult volunteers every 8 hours were 0.1, 0.2, 0.4 mg orally and 0.01 mg intranasally by rhinal tube. The results are shown in the following table:
### Mean Changes from Baseline (SE) in Pharmacodynamic Parameters in Normal Healthy Adult Volunteers

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total Urine Volume in mL</th>
<th>Maximum Urine Osmolality in mOsm/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1 mg PO q8h</td>
<td>-3689.3 (149.6)</td>
<td>514.8 (21.9)</td>
</tr>
<tr>
<td>0.2 mg PO q8h</td>
<td>-4429.9 (149.6)</td>
<td>686.3 (21.9)</td>
</tr>
<tr>
<td>0.4 mg PO q8h</td>
<td>-4998.8 (149.6)</td>
<td>769.3 (21.9)</td>
</tr>
<tr>
<td>0.01 mg IN q8h</td>
<td>-4844.9 (149.6)</td>
<td>754.1 (21.9)</td>
</tr>
</tbody>
</table>

(SE) = Standard error of the mean

With respect to the mean values of total urine volume decrease and maximum urine osmolality increase from baseline, the 90% confidence limits estimated that the 0.4 mg and 0.2 mg oral dose produced between 95% and 110% and 84% to 99% of pharmacodynamic activity, respectively, when compared to the 0.01 mg intranasal dose.

While both the 0.2 mg and 0.4 mg oral doses are considered pharmacodynamically similar to the 0.01 mg intranasal dose, the pharmacodynamic data on an inter-subject basis was highly variable and, therefore, individual dosing is recommended.

In another study in diabetes insipidus patients, the pharmacodynamic characteristics of DDAVP Tablets and intranasal formulations were compared over a 12-hour period. Ten fluid-controlled patients under age 18 were administered tablet doses of 0.2 mg and 0.4 mg, and intranasal doses of 0.01 mg and 0.02 mg.

### Mean Peak Pharmacodynamic Parameters in Pediatric and Adolescent Diabetes Insipidus Patients

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Urine Volume in mL/min</th>
<th>Maximum Urine Osmolality in mOsm/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01 mg IN</td>
<td>0.3 (0.15)</td>
<td>717.0 (224.63)</td>
</tr>
<tr>
<td>0.02 mg IN</td>
<td>0.3 (0.25)</td>
<td>761.8 (298.82)</td>
</tr>
<tr>
<td>'0.2 mg PO</td>
<td>0.3 (0.25)</td>
<td>761.8 (298.82)</td>
</tr>
<tr>
<td>0.4 mg PO</td>
<td>0.2 (0.15)</td>
<td>678.3 (147.91)</td>
</tr>
</tbody>
</table>

(SD) = Standard Deviation

All four dose formulations (0.01 mg IN, 0.02 mg IN, 0.2 mg PO and 0.4 mg PO) have a similar, pronounced pharmacodynamic effect on urine volume and urine osmolality. At two hours after study drug administration, mean urine volume was 4 mL/min and urine osmolality was >500 mOsm/kg. Mean plasma osmolality remained relatively constant over the time course recorded (0 to 12 hours). A statistical separation from baseline did not occur at any dose or time point. In these patients, the 0.2 mg tablets and the 0.01 mg intranasal spray exhibited similar pharmacodynamic profiles as did the 0.4 mg tablets and the 0.02 mg intranasal spray formulation. In another study of adult diabetes insipidus patients previously controlled on DDAVP intranasal spray, after one week of self-titration from spray to tablets, patients’ diuresis was controlled with 0.1 mg DDAVP Tablets three times a day.

**Primary Nocturnal Enuresis:** Two double-blind, randomized, placebo-controlled studies were conducted in 340 patients with primary nocturnal enuresis. Patients were 5-17 years old, and 72% were males. A total of 329 patients were evaluated for efficacy. Patients were evaluated over a two-week baseline period in which the average number of wet nights was 10 (range 4-14). Patients were then randomized to receive 0.2, 0.4, or 0.6 mg of DDAVP or placebo. The pooled results after two weeks are shown in the following table:
## Response to DDAVP and Placebo at Two Weeks of Treatment
### Mean (SE) Number of Wet Nights/2 Weeks

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 85)</th>
<th>0.2 mg/day (n = 79)</th>
<th>0.4 mg/day (n = 82)</th>
<th>0.6 mg/day (n = 83)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>10 (0.3)</td>
<td>11 (0.3)</td>
<td>10 (0.3)</td>
<td>10 (0.3)</td>
</tr>
<tr>
<td>Reduction from</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>1 (0.3)</td>
<td>3 (0.4)</td>
<td>3 (0.4)</td>
<td>4 (0.4)</td>
</tr>
<tr>
<td>Percent Reduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>from Baseline</td>
<td>10%</td>
<td>27%</td>
<td>30%</td>
<td>40%</td>
</tr>
<tr>
<td>p-value vs placebo</td>
<td></td>
<td>&lt;0.05</td>
<td>&lt;0.05</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

Patients treated with DDAVP Tablets showed a statistically significant reduction in the number of wet nights compared to placebo-treated patients. A greater response was observed with increasing doses up to 0.6 mg. In a six month, open-label extension study, patients completing the placebo-controlled studies were started on 0.2 mg/day DDAVP, and the dose was progressively increased until the optimal response was achieved (maximum dose 0.6 mg/day). A total of 230 patients were evaluated for efficacy; the average number of wet nights/2 weeks during the untreated baseline period was 10 (range 4-14), and the average duration (SD) of treatment was 4.2 (1.8) months. Twenty-five (25) patients (11%) achieved a complete or near complete response (≤2 wet nights/2 weeks) and did not require titration to the 0.6 mg/day dose. The majority of patients (198 of 230, 86%) were titrated to the highest dose. When all dose groups were combined, 128 (56%) showed at least a 50% reduction from baseline in the number of wet nights/2 weeks, while 87 (38%) patients achieved a complete or near complete response.

**Human Pharmacokinetics:** DDAVP is mainly excreted in the urine. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe renal impairment (n=24, 6 subjects in each group) receiving single dose desmopressin acetate (2mcg) injection demonstrated a difference in DDAVP terminal half-life. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment. (See CONTRAINDICATIONS.)

### INDICATIONS AND USAGE
**Central Diabetes Insipidus:** DDAVP Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP can be monitored by measuring urine volume and osmolality.

**Primary Nocturnal Enuresis:** DDAVP Tablets are indicated for the management of primary nocturnal enuresis. DDAVP may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.

### CONTRAINDICATIONS
DDAVP Tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of DDAVP Tablets.

DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).

### WARNINGS
When DDAVP Tablets are administered, in particular in pediatric and geriatric patients, fluid intake should be adjusted downward to decrease the potential occurrence of water intoxication and hyponatremia with accompanying signs and symptoms (headache, nausea/vomiting, decreased serum sodium and weight gain). (See PRECAUTIONS, Geriatric Use.) Particular
attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that may result in seizures which could lead to coma.

**PRECAUTIONS**

**General:** Intranasal formulations of DDAVP at high doses and DDAVP Injection have infrequently produced a slight elevation of blood pressure which disappears with a reduction of dosage. Although this effect has not been observed when single oral doses up to 0.6 mg have been administered, the drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease, because of a possible rise in blood pressure.

DDAVP should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, since these patients may develop hyponatremia.

Rare severe allergic reactions have been reported with DDAVP. Anaphylaxis has been reported rarely with intravenous and intranasal administration of DDAVP but not with **DDAVP Tablets.**

**Laboratory Tests:** **Central Diabetes Insipidus:** Laboratory tests for monitoring the patient with central diabetes insipidus or post-surgical or head trauma-related polyuria and polydipsia include urine volume and osmolality. In some cases, measurements of plasma osmolality may be useful.

**Drug Interactions:** Although the pressor activity of DDAVP is very low compared to its antiuretic activity, large doses of **DDAVP Tablets** should be used with other pressor agents only with careful patient monitoring.

**Carcinogenicity, Mutagenicity, Impairment of Fertility:** Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

**Pregnancy:** **Category B:** Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 mcg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m²) revealed no harm to the fetus due to DDAVP® (desmopressin acetate). There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Several publications where desmopressin acetate was used in the management of diabetes insipidus during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. However, no causal connection between these events and desmopressin acetate has been established. A fifteen year Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that in the general population; however, the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in antiuretic doses has no uterotonic action and the physician will have to weigh the possible therapeutic advantages against the possible risks in each case.

**Nursing Mothers:** There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP in breast milk following an intranasal dose of 0.01 mg.

It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to nursing mothers.

**Pediatric Use:** **Central Diabetes Insipidus:** **DDAVP® Tablets** (desmopressin acetate) have been used safely in pediatric patients, age 4 years and older, with diabetes insipidus for periods up to 44 months. In younger pediatric patients the dose must be individually adjusted in order to prevent an excessive decrease in plasma osmolality leading to hyponatremia and possible convulsions; dosing should start at 0.05 mg (1/2 of the 0.1 mg tablet). Use of **DDAVP Tablets** in pediatric patients requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication.

**Primary Nocturnal Enuresis:** **DDAVP Tablets** have been safely used in pediatric patients age 6 years and older with primary nocturnal enuresis for up to 6 months. Some patients respond to a dose of 0.2 mg; however, increasing responses are seen at doses of 0.4 mg and 0.6 mg. No increase in the frequency or severity of adverse reactions or decrease in efficacy was seen with an increased dose or duration. The dose should be individually adjusted to achieve the best results.

**Geriatric Use:** Clinical studies of DDAVP Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).
(See CLINICAL PHARMACOLOGY, Human Pharmacokinetics and CONTRAINDICATIONS.)
Use of DDAVP Tablets in geriatric patients requires careful fluid intake restrictions to prevent possible hyponatremia and water intoxication. (See WARNINGS.)

ADVERSE REACTIONS
Infrequently, large doses of the intranasal formulations of DDAVP and DDAVP Injection have produced transient headache, nausea, flushing and mild abdominal cramps. These symptoms have disappeared with reduction in dosage.

Central Diabetes Insipidus: In long-term clinical studies in which patients with diabetes insipidus were followed for periods up to 44 months of DDAVP Tablet therapy, transient increases in AST (SGOT) no higher than 1.5 times the upper limit of normal were occasionally observed. Elevated AST (SGOT) returned to the normal range despite continued use of DDAVP Tablets.

Primary Nocturnal Enuresis: The only adverse event occurring in ≥3% of patients in controlled clinical trials with DDAVP Tablets that was probably, possibly, or remotely related to study drug was headache (4% DDAVP, 3% placebo).

Other: The following adverse events have been reported; however their relationship to DDAVP has not been established: abnormal thinking, diarrhea, and edema-weight gain.

See WARNINGS for the possibility of water intoxication and hyponatremia.

OVERDOSAGE
(See ADVERSE REACTIONS.) In case of overdose, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. There is no known specific antidote for DDAVP. The patient should be observed and treated with appropriate symptomatic therapy.
An oral LD₅₀ has not been established. Oral doses up to 0.2 mg/kg/day have been administered to dogs and rats for 6 months without any significant drug-related toxicities reported. An intravenous dose of 2 mg/kg in mice demonstrated no effect.

DOSAGE AND ADMINISTRATION
Central Diabetes Insipidus: The dosage of DDAVP Tablets must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients previously on intranasal DDAVP therapy should begin tablet therapy twelve hours after the last intranasal dose. During the initial dose titration period, patients should be observed closely and appropriate safety parameters measured to assure adequate response. Patients should be monitored at regular intervals during the course of DDAVP Tablet therapy to assure adequate antidiuretic response. Modifications in dosage regimen should be implemented as necessary to assure adequate water turnover.

Adults and Children: It is recommended that patients be started on doses of 0.05 mg (1/2 of the 0.1 mg tablet) two times a day and individually adjusted to their optimum therapeutic dose. Most patients in clinical trials found that the optimal dosage range is 0.1 mg to 0.8 mg daily, administered in divided doses. Each dose should be separately adjusted for an adequate diurnal rhythm of water turnover. Total daily dosage should be increased or decreased in the range of 0.1 mg to 1.2 mg divided into two or three daily doses as needed to obtain adequate antidiuresis. See Pediatric Use subsection for special considerations when administering desmopressin acetate to
pediatric diabetes insipidus patients.

**Geriatric Use:** This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics, CONTRAINDICATIONS, and PRECAUTIONS, Geriatric Use.)

**Primary Nocturnal Enuresis:** The dosage of DDAVP Tablets must be determined for each individual patient and adjusted according to response. Patients previously on intranasal DDAVP therapy can begin tablet therapy the night following (24 hours after) the last intranasal dose. The recommended initial dose for patients age 6 years and older is 0.2 mg at bedtime. The dose may be titrated up to 0.6 mg to achieve the desired response.

### HOW SUPPLIED

<table>
<thead>
<tr>
<th>Strength</th>
<th>Size</th>
<th>NDC 0075-</th>
<th>Color</th>
<th>Markings</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1 mg</td>
<td>Bottle of 100</td>
<td>0016-00</td>
<td>White</td>
<td>[Image]</td>
</tr>
<tr>
<td>0.2 mg</td>
<td>Bottle of 100</td>
<td>0026-00</td>
<td>White</td>
<td>[Image]</td>
</tr>
</tbody>
</table>

Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP]. Avoid exposure to excessive heat or light.

This product should be dispensed in a container with a child-resistant cap.

**Keep out of the reach of children.**

U.S. Patent Nos. 5,500,413; 5,596,078; 5,674,850; 5,047,398; 5,763,407

Manufactured for
Aventis Pharmaceuticals Inc.
Bridgewater, NJ 08807 USA
By Ferring AB, Soldattorpsvägen 5, SE-200 61 Limhamn, Sweden
Rev. XXXX

©2004 Aventis Pharmaceuticals Inc.
APPLICATION NUMBER:

NDA 18-938/S-017

ADMINISTRATIVE DOCUMENTS
AND
CORRESPONDENCE
DIVISION OF METABOLIC AND ENDOCRINE DRUG PRODUCTS

CONSUMER SAFETY OFFICER LABEL REVIEW

Application Number: NDA 18-938/S-017

Name of Drug: DDAVP (desmopressin acetate) Injection

Sponsor: Aventis Pharmaceuticals

Material Reviewed:

Submission Date: February 11, 2002

Receipt Date: February 12, 2002

Background and Summary

This product DDAVP (desmopressin acetate) Injection, 4μg/mL, is approved for antidiuretic therapy in the management of central (cranial) diabetes insipidus and for the management of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is marketed in presentations; e.g. 1 mL single dose vials, 10 mL multiple dose vials. The subject of this supplement is the carton for ten single dose 1-mL 4μg/mL ampules.

This submission dated February 11, 2002, was submitted as a “Changes Being Effected Supplement.”

For comparison of the labeling submitted to S-017 to the currently approved carton labeling the following information was obtained from previous submissions to this NDA:

S-007 contained the currently approved carton labeling. This supplement provides a deletion of the chlorobutanol acetate for the 1 mL ampules for the 4 μg/ml concentration of desmopressin acetate. S-007 with labeling was approved in a letter dated April 22, 2002, as FPL. No Supplements submitted between S-011 and this supplement contained labeling revisions to the carton.

S-011 dated January 16, 1995 and approved April 25, 1995 provided for the addition of a 15 μg/mL strength. Final approved labeling for the package insert, carton and vial label was submitted on August 18, 1995. An “Acknowledge and Retain” letter approving the FPL submitted was sent February 7, 1996.
Supplement S-013 submitted on August 17, 1998, contained revisions to the package insert, DOSAGE AND ADMINISTRATION and HOW SUPPLIED sections but not to the carton labeling.

Supplements submitted before and after S-017 contained no revisions to the carton labeling (S-016, S-010, S-015, S-014).

**Review**

The labeling submitted as a CBE supplement, dated February 11, 2002, contained the carton label, ID # 407108 which included changes in the carton label as follows:

- Instructions regarding how to use the one point cut DDAVP ampules

- Changes in the company name from Rhone-Poulenc Rorer to Aventis Pharmaceuticals Products Inc.

- Minor graphic changes

- Change the caution statement to Rx only

- Change the address for Ferring AB

The above labeling was compared with the currently approved label for S-007 for carton label (ID #CR-4709D, no revision date). S-007 with carton label was approved on April 22, 1992. The following changes were noted:

1. The legend "preservative free 10 ampules 1 mL, 4mcg/mL" with an outline of an ampule has been changed. The strength "4mcg/mL" is much more prominent and immediately follows the proprietary and established names. The phrase "Preservative Free" appears below the strength and is isolated by blank space. Near the bottom of the front panel appears "Ten 1 mL Ampules."

2. The company’s name has been changed from Rhone-Poulenc Rorer to Aventis, and a logo appears to the left of Aventis.
3. The description of the product which read:

Each mL provides:
Desmopressin acetate . . . 4 mcg
sodium chloride ........... 9 mg
Hydrochloric acid to adjust pH to 4.0.

has been changed to read:

4. The Caution statement:

“Caution: Federal (U.S.A.) law prohibits dispensing without a prescription.”

has been deleted from the middle of the back panel. Now “Rx only” appears at the top of
the back panel.

5. The following has been added to the back panel of the carton label:

Dosage and Administration: See package insert for dosage administration.

WARNING: Keep out of reach of children.

Store refrigerated 2 to 8°C (36 to 46°F).

Mfd by:
Ferring AB
Soldattorpsvagen 5
SE-200 61 Limhamn
Sweden
Mtd for:
Aventis Pharmaceuticals Products Inc.
Bridgewater, NJ 08007 ©2000
Made in Sweden
www.aventispharma-us.com
50059276
6. Directions for use of the OPC ampules* for DDAVP Injection have been added as follows:

Directions for use of OPC ampules* for DDAVP Injection

1. Use aseptic technique to clean ampule. Gently tap the top of the ampule to assist the flow of the solution from the upper portion of the ampule to the lower portion.
2. Locate the blue dot on the upper portion of the ampule. Below this dot is a small score on the neck of the ampule. Hold the ampule with the blue dot facing away from you.
3. Cover the vial with an appropriate wipe. Apply pressure to the top and bottom portions of the ampule to snap the ampule open away from you.

* One Point Cut

Reviewer's Comments: The changes proposed to the carton labeling for S-017 were reviewed by Dr. Chien-Hua Niu, the reviewing chemist, and myself and were found to be acceptable.

Conclusions

The draft carton labeling submitted for S-017 is approvable. A letter approving the labeling revisions for the carton label as submitted should be drafted.

______________________________
Steve McCort
Regulatory Project Manager, HFD-510

Supervisory Comment/Concurrence:

______________________________
Enid Galliers
Chief, Project Management Staff
CSO LABELING REVIEW
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-------------------------------
Stephen McCort
8/8/02 11:59:54 AM
CSO

Enid Galliers
8/8/02 12:10:03 PM
CSO
NDA 18-938/S-017

Aventis Pharmaceuticals Products, Inc.
Attention: Susan Witham, Director, Drug Regulatory Affairs
Route 202-206
P.O. Box 6800
Bridgewater, NJ 08807-0800

Dear Ms. Witham:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: DDAVP (desmopressin acetate) Injection
NDA Number: 18-938
Supplement Number: S-017
Date of Supplement: February 11, 2002
Date of Receipt: February 12, 2002

This supplemental application, submitted as a "Supplement - Changes Being Effected" supplement, proposes changes to instructions regarding how to use the one point cut DDAVP ampules; the company name from Rhone-Poulenc Rorer to Aventis Pharmaceuticals Products, Inc.; graphics, the caution statement to Rx Only, the address for Ferring AB.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on April 13, 2002, in accordance with 21 CFR 314.101(a).
Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:

**U.S. Postal/Courier/Overnight Mail:**

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Metabolic and Endocrine Drug Products, HFD-510  
Attention: Division Document Room  
5600 Fishers Lane  
Rockville, Maryland 20857

If you have any questions, call me at (301) 827-6415.

Sincerely,

[See appended electronic signature page]

Steve McCort  
Regulatory Project Manager  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kati Johnson
5/28/02 07:36:07 AM
signing for Steve McCort